Pub. Date : 2020 Apr
PMID : 31752581
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 2 | Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with intensive chemotherapy for patients with FLT3-mutant AML. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 3 | Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with intensive chemotherapy for patients with FLT3-mutant AML. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 4 | Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with intensive chemotherapy for patients with FLT3-mutant AML. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 5 | Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with intensive chemotherapy for patients with FLT3-mutant AML. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |